Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1697-1711

  Kim, Do Hyung ^a,b   Jeong, Young Il ^a   Chung, Chung Wook ^a   Kim, Cy Hyun ^a,b   Kwak, Tae Won ^a   Lee, Hye Myeong ^a   Kang, Dae Hwan ^a,b  

^a Yangsan Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Biliary stent; Human cholangiocarcinoma cells; Polycaprolactone; Sorafenib

Indexed keywords

CASPASE 3; FAS ANTIGEN; GELATINASE A; GELATINASE B; JANUS KINASE; POLYCAPROLACTONE; PROTEIN BCL 2; PROTEIN BCL X; SORAFENIB; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COATING; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELUTING STENT; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS; BILIARY STENT; HUMAN CHOLANGIOCARCINOMA CELLS; POLYCAPROLACTONE; SORAFENIB;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLANGIOCARCINOMA; DRUG EVALUATION, PRECLINICAL; DRUG-ELUTING STENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYESTERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876968027     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43508     Document Type: Article

References (37)

1. Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int. 2009;9:3.
2. Nakajima T, Kondo Y, Miyazaki M, Okui K. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol. 1988;19(10):1228-1234.
3. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004;66(3):167-179.
4. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002;29(6 Suppl 20):40-45.
5. Cereda S, Passoni P, Reni M, et al. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer. 2010;116(9):2208-2214.
6. Hong YS, Lee J, Lee SC, et al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol. 2007;60(3):321-328.
7. Kim ST, Park JO, Lee J, et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 2006;106(6):1339-1346.
8. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281.
9. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 Study. Br J Cancer. 2009;101(4):621-627.
10. Park SW, Lee DH, Park YS, Chung JB, Kang JK, Song SY. Percutaneous transhepatic choledochoscopic injection of ethanol with OK-432 mixture for palliation of malignant biliary obstruction. Gastrointest Endosc. 2003;57(6):769-773.
11. Lee DH. [Drug-eluting stent in gastrointestinal disease.] Korean J Gastroenterol. 2007;49(5):294-299. Korean.
12. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140.
13. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851-11858.
14. Qun W, Tao Y. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. Hepatogastroenterology. 2010;57(99-100):426-429.
15. LaRocca RV, Hicks MD, Mull L, Foreman B. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. J Gastrointest Cancer. 2007;38(2-4):154-156.
16. Wiedmann MW, Mossner J. Molecular targeted therapy of biliary tract cancer - results of the first clinical studies. Curr Drug Targets. 2010;11(7):834-850.
17. Sugiyama H, Onuki K, Ishige K, et al. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol. 2011;46(6):779-789.
18. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 2007;73(9):1308-1317.
19. Jin SG, Jeong YI, Jung S, Ryu HH, Jin YH, Kim IY. The effect of hyaluronic acid on the invasiveness of malignant glioma cells: comparison of invasion potential at hyaluronic acid hydrogel and matrigel. J Korean Neurosurg Soc. 2009;46(5):472-478.
20. Okabe H, Beppu T, Hayashi H, et al. Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells. Ann Surg Oncol. 2011;18(4):1175-1184.
21. Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol. 2003;181(3):819-827.
22. Shen FZ, Zhang BY, Feng YJ, et al. Current research in perineural invasion of cholangiocarcinoma. J Exp Clin Cancer Res. 2010;29:24.
23. Gores GJ. Cholangiocarcinoma: preventing invasion as anti-cancer strategy. J Hepatol. 2003;38(5):671-673.
24. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41(1):5-15.
25. Mezawa S, Homma H, Sato T, et al. A study of carboplatin-coated tube for the unresectable cholangiocarcinoma. Hepatology. 2000;32(5):916-923.
26. Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102(1):68-72.
27. El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646-1651.
28. Woo HY, Heo J, Yoon KT, et al. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2012;47(7):809-819.
29. Xinopoulos D, Dimitroulopoulos D, Karanikas I, et al. Gemcitabine as palliative treatment in patients with unresectable pancreatic cancer previously treated with placement of a covered metal stent. A randomized controlled trial. J BUON. 2008;13(3):341-347.
30. Chung MJ, Kim H, Kim KS, Park S, Chung JB, Park SW. Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model. J Gastroenterol Hepatol. 2012;27(2):261-267.
31. Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev. 2006;58(3):387-401.
32. Smith EJ, Rothman MT. Antiproliferative coatings for the treatment of coronary heart disease: what are the targets and which are the tools? J Interv Cardiol. 2003;16(6):475-483.
33. McLean DR, Eiger NL. Stent design: implications for restenosis. Rev Cardiovasc Med. 2002;3 Suppl 5:S16-S22.
34. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology. 1996;23(6):1341-1344.
35. Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer. 2002;94(2):428-434.
36. Subimerb C, Pinlaor S, Khuntikeo N, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep. 2010;3(4):597-605.
37. Kirimlioǧlu H, Türkmen I, Başsüllü N, Dirican A, Karadaǧ N, Kirimlioǧlu V. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. Turk J Gastroenterol. 2009;20(1):41-47.